DOCSLIB.ORG

Biochemical Methods for Preparation and Study of Peptide Natural Product Libraries

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biochemical Methods for Preparation and Study of Peptide Natural Product Libraries BIOCHEMICAL METHODS FOR PREPARATION AND STUDY OF PEPTIDE NATURAL PRODUCT LIBRARIES Steven Robert Fleming A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Pharmaceutical Sciences in the Doctoral Program of the UNC Eshelman School of Pharmacy (Division of Chemical Biology & Medicinal Chemistry) Chapel Hill 2020 Approved by: Albert A. Bowers Michael B. Jarstfer Rihe H. Liu Kevin M. Weeks Leslie M. Hicks ©2020 Steven Robert Fleming ALL RIGHTS RESERVED ii ABSTRACT Steven Robert Fleming: Biochemical Methods for Preparation and Study of Peptide Natural Product Libraries (Under the direction of Albert Bowers) mRNA Display is an increasingly popular technique in pharmaceutical sciences to make highly diverse peptide libraries to pan for protein inhibitors. The current state of the art applies Flexizyme codon reprogramming with mRNA display to introduce unnatural amino acids for peptide cyclization and to further increase library diversity. Interestingly, ribosomally synthesized and post-translationally modified peptides (RiPP) are a unique class of natural products that transform linear peptides into highly modified and structurally complex metabolites. By combining RiPP biosynthesis with mRNA display, libraries of increasingly greater diversity can be achieved, and impending selected inhibitors will have natural product-like qualities, which we expect will allow these compounds to have better drug-like properties. Herein, we have developed a platform to measure RiPP enzyme modification of mRNA display libraries to show for the first time that RiPP enzymes can modify RNA linked peptide substrates. The platform may be extrapolated to many different RiPP enzymes and provides useful measurements to determine if a RiPP enzyme is promiscuous and effective to produce highly diversified peptides. Thiopeptides are a specific class of RiPP that we would like to apply to mRNA display, because they have broad activities. Additionally, the structure of thiopeptides is primed for mRNA display protocols, consisting of a highly decorated macrocycle with a C-terminal tail that may readily accept an iii mRNA tag. We present a redesigned chemoenzymatic strategy to make thiopeptides using cell free protein synthesis that is promiscuous, can synthesize different thiopeptide classes, and is mRNA display ready. Finally, bioinformatic analysis of publicly available thiopeptide gene clusters shows that many unknown thiopeptides still exist. We have organized a set of 14 new clusters for which we can apply our chemoenzymatic strategy and characterize these unknown compounds, with the hope of finding the best thiopeptide enzymes for use in mRNA display selections. iv To God v ACKNOWLEDGMENTS I would first like to thank my family. Thank you for prioritizing my education and always encouraging me to work hard and do my best. I would not be here without you. Thank you, Dr. Bowers, for taking me into the group, for training me, and for helping to shape my future. I am very happy and thankful to be a chemical biologist and time spent in your lab has been a delight. A special thanks to all the Bowers’ lab alumni whom I’ve had the pleasure to interact with: Dr. Scott Allen, Dr. Walter Wever, Dr. Rachel Bleich, Dr. Paul Himes, Dr. Swapnil Ghodge, Dr. Jon Bogart, Dr. Kelly Bird, Dr. Nick Kramer, Matt Fleming, Tory Haberman, Bree Iskandar, Matt Bowler, Jarrett Pelton, Braxton Cline, and Sungwan Hwang. Lab has been a great place to be, and that is because of you all. A doubly special thanks to Dr. Paul Himes for being my lab mentor and teaching me many basic research skills. Thank you for all of the hard work you put into the development of mRNA display. I would like to thank those on my doctoral committee whose discussions and advice have been invaluable during my Ph.D. training. Thank you, Dr. Mike Jarstfer, for serving as my chair, providing letters of recommendation, and often reaching out with opportunities to present my work. Thank you, Dr. Rihe Liu, for allowing me to rotate in your lab where my interest in mRNA display began. Thank you, Dr. Kevin Weeks, for teaching me to write an abstract. Lastly, but not least, thank you, Dr. Leslie Hicks, for collaborating with me and giving me access to your mass spectrometers. This was absolutely vital for our first publication. vi TABLE OF CONTENTS LIST OF TABLES …………………………………………………………………………......... xi LIST OF FIGURES …………………………………………………………………………..… xii LIST OF ABBREVIATIONS ……………………………………………………………..…... xiv CHAPTER 1: INTRODUCTION ………………………………………………………..………. 1 1.1 Modification of Genetically Encoded Peptide Libraries and Drug Discovery ………. 1 1.2 mRNA Display Has Specific Advantages Over Other Display Technologies ………. 1 1.3 RiPPs Biosynthesis and Application to mRNA Display ………………………..…… 3 1.4 Thiopeptides are a Good Scaffold for mRNA Display Selections ………………...… 4 1.5 Bioinformatic Expansion of Thiopeptides and Chemoenzymatic Synthesis Could Lead to Optimal Enzymes for mRNA Display of Thiopeptides………………. 7 REFERENCES……………………………………………………………………………….…... 9 CHAPTER 2: EXPLORING THE POST-TRANSLATIONAL ENZYMOLOGY OF PAAA BY MRNA DISPLAY…………………………………………………………….… 13 2.1 Introduction ……………………………………………………………………….... 13 2.2 Results and Discussion ……………………………………………………………… 14 2.3 Conclusion ……………………………..…………………………………………… 20 2.4 Experimental ………………………………………………………………………... 20 2.4.1 Materials and General Methods ………………………………………...… 20 2.4.2 Expression and Purification of PaaA-His6 ……………………………...... 22 2.4.3 DNA Preparation for NEB PURExpress Translations ……………………. 23 vii 2.4.4 DNA Preparation of Transcription Templates …………………………..… 23 2.4.5 Transcription with T7 RNA polymerase and Urea Gel Purification ……… 27 2.4.6 N-Biotin-L-Phenylalanine itRNA Acylation Conditions …………….…… 28 2.4.7 mRNA Display Protocols …………………………………………………. 29 2.4.8 MALDI-TOF Experiments ……………………………………………….. 36 2.4.9 Binding Experiments ………………………………………………….….. 36 2.4.10 Peptide Synthesis ………………………………………………………... 37 REFERENCES ……………………...………………………………………………………….. 41 CHAPTER 3: FLEXIZYME ENABLED BENCHTOP BIOSYNTHESIS OF THIOPEPTIDES …..…………………………………………………………………………… 44 3.1 Introduction ………………………………………………………………………… 44 3.2 Results and Discussion ……………………………………………………………… 47 3.3 Conclusion …………………………………………………..……………………… 53 3.4 Experimental ………………………………………………………………………... 53 3.4.1 General Information ….……………………………………….………...... 53 3.4.2 Protein Cloning ………………………………………………….………... 54 3.4.3 Protein Expression Purification ……….………………………………...... 55 3.4.4 Protein Sequences …………………….…………………………………... 59 3.4.5 DNA and RNA Preparation ……….……………………………………… 62 3.4.6 Flexizyme tRNA Acylation of Se-phenylselenocysteine ……….………… 66 3.4.7 Translations …………………………………………………….……….... 66 3.4.8 Enzyme Reactions and Oxidative Elimination …………….……………… 67 3.4.9 Desalting Protocol and Preparation for LC / MS …………….………….... 68 3.4.10 Synthesis of Se-phenylselenocysteine dinitrobenzyl ester …….………… 68 viii 3.4.11 Liquid Chromatography and Mass Spectrometry …….………………..... 70 REFERENCES………………………………………………………………………………….. 72 CHAPTER 4: BIOINFORMATIC EXPANSION OF THIOPEPTIDES AND PRIORITIZATION FOR CHEMOENZYMATIC DISCOVERY……………………………… 75 4.1 Introduction ……………………………………………………………………….... 75 4.2 Diversity of the Publicly Available Pyridine Synthases from Thiopeptide Biosynthesis ...…………………………………………………….…... 77 4.3 Diversity of Thiopeptide Precursor Peptides ……………………………………….. 80 4.4 Prioritization of Unknown Thiopeptide Biosynthetic Gene Clusters for Chemoenzymatic Discovery …………………………………….. 84 4.5 Diversity of Thiopeptide Binding Receptors ………………………………………... 87 4.6 Conclusion ………………………………………………………………………….. 90 4.7 Experimental ………………………………………………………………………... 91 4.7.1 Collecting pyridine synthases from GenBank and RODEO ……………… 91 4.7.2 Curating Thiopeptide Precursor Peptides ………………………………… 97 4.7.3 Creating Sequence Similarity Networks ………………………………….. 97 4.7.4 WEBLOGOs for Predicted Thiopeptide Cores …………………………… 97 4.7.5 Thiopeptide Predicted Gene Clusters with antiSMASH ………………….. 98 REFERENCES………………………………………………………………………………….. 99 CHAPTER 5. CONCLUSION ………………………………………………………………... 103 5.1 Concluding Remarks ………………………………………………………….…… 103 REFERENCES………………………………………………………………………………… 106 APPENDIX A: SUPPLEMENTARY FIGURES AND TABLES FOR CHAPTER 2 …….…. 108 APPENDIX B: SUPPLEMENTARY TABLES AND FIGURES FOR CHAPTER 3 ……….. 164 REFERENCES ………………………………………………………………………………....191 ix APPENDIX C: SUPPLEMENTARY TABLES AND FIGURES FOR CHAPTER 4 …….…. 192 x LIST OF TABLES Table 2.1 - Taq polymerase amplification cycles for translation genes …………………….….. 23 Table 2.2 - Flexizyme and mRNA display primers ………………………………………..…… 24 Table 2.3 - Extension Protocol …………………………………………………………….…… 24 Table 2.4 - PCR1 Protocol …………………………………………………………………..….. 25 Table 2.5 - PCR2 protocol ………………………………………………………………..…….. 25 Table 2.6 - PCR3 protocol …………………………………………………………………..….. 25 Table 2.7 - PCR4 protocol ……………………………………………………………..……….. 25 Table 3.1 - Results of flexizyme-enabled benchtop biosynthesis with mutant leader peptides and cores …………………………………………………………..……. 49 Table 3.2 - Extension Protocol ……………………………………………………………..…… 62 Table 3.3 - PCR1 protocol …………………………………………………………………..….. 62 Table 3.4 - PCR2 protocol ………………………………………………………………..…….. 62 Table 3.5 - dFx and AsnE2 primers ……………………………………………………….……. 63 Table 3.6 - Q5 PCR amplification ………………………………………………………….…... 65 Table 3.7 - Taq PCR amplification ……………………………………………………….….….
Load more

Recommended publications
  • Natural Thiopeptides As a Privileged Scaffold for Drug Discovery and Therapeutic Development
    – MEDICINAL Medicinal Chemistry Research (2019) 28:1063 1098 CHEMISTRY https://doi.org/10.1007/s00044-019-02361-1 RESEARCH REVIEW ARTICLE Natural thiopeptides as a privileged scaffold for drug discovery and therapeutic development 1 1 1 1 1 Xiaoqi Shen ● Muhammad Mustafa ● Yanyang Chen ● Yingying Cao ● Jiangtao Gao Received: 6 November 2018 / Accepted: 16 May 2019 / Published online: 29 May 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Since the start of the 21st century, antibiotic drug discovery and development from natural products has experienced a certain renaissance. Currently, basic scientific research in chemistry and biology of natural products has finally borne fruit for natural product-derived antibiotics drug discovery. A batch of new antibiotic scaffolds were approved for commercial use, including oxazolidinones (linezolid, 2000), lipopeptides (daptomycin, 2003), and mutilins (retapamulin, 2007). Here, we reviewed the thiazolyl peptides (thiopeptides), an ever-expanding family of antibiotics produced by Gram-positive bacteria that have attracted the interest of many research groups thanks to their novel chemical structures and outstanding biological profiles. All members of this family of natural products share their central azole substituted nitrogen-containing six-membered ring and are fi 1234567890();,: 1234567890();,: classi ed into different series. Most of the thiopeptides show nanomolar potencies for a variety of Gram-positive bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and penicillin-resistant Streptococcus pneumonia (PRSP). They also show other interesting properties such as antiplasmodial and anticancer activities. The chemistry and biology of thiopeptides has gathered the attention of many research groups, who have carried out many efforts towards the study of their structure, biological function, and biosynthetic origin.
    [Show full text]
  • Actinobacteria in Algerian Saharan Soil and Description Sixteen New
    Revue ElWahat pour les Recherches et les Etudes Vol.7n°2 (2014) : 61 – 78 Revue ElWahat pour les recherches et les Etudes : 61 – 78 ISSN : 1112 -7163 Vol.7n°2 (2014) http://elwahat.univ-ghardaia.dz Diversity of Actinobacteria in Algerian Saharan soil and description of sixteen new taxa Bouras Noureddine 1,2 , Meklat Atika 1, Boubetra Dalila 1, Saker Rafika 1, Boudjelal Farida 1, Aouiche Adel 1, Lamari Lynda 1, Zitouni Abdelghani 1, Schumann Peter 3, Spröer Cathrin 3, Klenk Hans -Peter 3 and Sabaou Nasserdine 1 1- Affiliation: Laboratoire de Biologie des Systèmes Microbiens (LBSM), Ecole Normale Supérieure de Kouba, Alger, Algeria; [email protected] 2- Département de Biologie, Faculté des Sciences de la Nature et de la Vie et Sciences de la Terre, Université de Ghardaïa, BP 455, Ghardaïa 47000, Algeria; 3- Leibniz Institute DSMZ - Germ an Collection of Microorganisms and Cell Cultures, Inhoffenstraße 7B, 38124 Braunschweig, Germany. Abstract _ The goal of this study was to investigate the biodiversity of actinobacteria in Algerian Saharan soils by using a polyphasic taxonomic approach based on the phenotypic and molecular studies (16S rRNA gene sequence analysis and DNA-DNA hybridization ). A total of 323 strains of actinobacteria were isolated from different soil samples, by a dilution agar plating method, using selective isolation media without or with 15-20% of NaCl (for halophilic strains). The morphological and chemotaxonomic characteristics (diaminopimelic acid isomers, whole-cell sugars, menaquinones, cellular fatty acids and diagnostic phospholipids) of the strains were consistent with those of members of the genus Saccharothrix , Nocardiopsis , Actinopolyspora , Streptomonospora , Saccharopolyspora , Actinoalloteichus , Actinokineospora and Prauserella .
    [Show full text]
  • The Isolation of a Novel Streptomyces Sp. CJ13 from a Traditional Irish Folk Medicine Alkaline Grassland Soil That Inhibits Multiresistant Pathogens and Yeasts
    applied sciences Article The Isolation of a Novel Streptomyces sp. CJ13 from a Traditional Irish Folk Medicine Alkaline Grassland Soil that Inhibits Multiresistant Pathogens and Yeasts Gerry A. Quinn 1,* , Alyaa M. Abdelhameed 2, Nada K. Alharbi 3, Diego Cobice 1 , Simms A. Adu 1 , Martin T. Swain 4, Helena Carla Castro 5, Paul D. Facey 6, Hamid A. Bakshi 7 , Murtaza M. Tambuwala 7 and Ibrahim M. Banat 1 1 School of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK; [email protected] (D.C.); [email protected] (S.A.A.); [email protected] (I.M.B.) 2 Department of Biotechnology, University of Diyala, Baqubah 32001, Iraq; [email protected] 3 Department of Biology, Faculty of Science, Princess Nourah Bint Abdulrahman University, Riyadh 11568, Saudi Arabia; [email protected] 4 Institute of Biological, Environmental & Rural Sciences (IBERS), Aberystwyth University, Gogerddan, Ab-erystwyth, Wales SY23 3EE, UK; [email protected] 5 Instituto de Biologia, Rua Outeiro de São João Batista, s/nº Campus do Valonguinho, Universidade Federal Fluminense, Niterói 24210-130, Brazil; [email protected] 6 Institute of Life Science, Medical School, Swansea University, Swansea, Wales SA2 8PP, UK; [email protected] 7 School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK; [email protected] (H.A.B.); [email protected] (M.M.T.) * Correspondence: [email protected] Abstract: The World Health Organization recently stated that new sources of antibiotics are urgently Citation: Quinn, G.A.; Abdelhameed, required to stem the global spread of antibiotic resistance, especially in multiresistant Gram-negative A.M.; Alharbi, N.K.; Cobice, D.; Adu, bacteria.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al
    USOO9642912B2 (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak et al. (45) Date of Patent: *May 9, 2017 (54) TOPICAL FORMULATIONS FOR TREATING (58) Field of Classification Search SKIN CONDITIONS CPC ...................................................... A61K 31f S7 (71) Applicant: Crescita Therapeutics Inc., USPC .......................................................... 514/171 Mississauga (CA) See application file for complete search history. (72) Inventors: Edward T. Kisak, San Diego, CA (56) References Cited (US); John M. Newsam, La Jolla, CA (US); Dominic King-Smith, San Diego, U.S. PATENT DOCUMENTS CA (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Santa Barbara, 5,602,183 A 2f1997 Martin et al. CA (US); Wade A. Hull, Kaysville, UT 5,648,380 A 7, 1997 Martin 5,874.479 A 2, 1999 Martin (US); Ngoc Truc-ChiVo, Longueuil 6,328,979 B1 12/2001 Yamashita et al. (CA) 7,001,592 B1 2/2006 Traynor et al. 7,795,309 B2 9/2010 Kisak et al. (73) Assignee: Crescita Therapeutics Inc., 8,343,962 B2 1/2013 Kisak et al. Mississauga (CA) 8,513,304 B2 8, 2013 Kisak et al. 8,535,692 B2 9/2013 Pongpeerapat et al. (*) Notice: Subject to any disclaimer, the term of this 9,308,181 B2* 4/2016 Kisak ..................... A61K 47/12 patent is extended or adjusted under 35 2002fOOO6435 A1 1/2002 Samuels et al. 2002fOO64524 A1 5, 2002 Cevc U.S.C. 154(b) by 204 days. 2005, OO 14823 A1 1/2005 Soderlund et al. This patent is Subject to a terminal dis 2005.00754O7 A1 4/2005 Tamarkin et al.
    [Show full text]
  • Improved Taxonomy of the Genus Streptomyces
    UNIVERSITEIT GENT Faculteit Wetenschappen Vakgroep Biochemie, Fysiologie & Microbiologie Laboratorium voor Microbiologie Improved taxonomy of the genus Streptomyces Benjamin LANOOT Scriptie voorgelegd tot het behalen van de graad van Doctor in de Wetenschappen (Biochemie) Promotor: Prof. Dr. ir. J. Swings Co-promotor: Dr. M. Vancanneyt Academiejaar 2004-2005 FACULTY OF SCIENCES ____________________________________________________________ DEPARTMENT OF BIOCHEMISTRY, PHYSIOLOGY AND MICROBIOLOGY UNIVERSITEIT LABORATORY OF MICROBIOLOGY GENT IMPROVED TAXONOMY OF THE GENUS STREPTOMYCES DISSERTATION Submitted in fulfilment of the requirements for the degree of Doctor (Ph D) in Sciences, Biochemistry December 2004 Benjamin LANOOT Promotor: Prof. Dr. ir. J. SWINGS Co-promotor: Dr. M. VANCANNEYT 1: Aerial mycelium of a Streptomyces sp. © Michel Cavatta, Academy de Lyon, France 1 2 2: Streptomyces coelicolor colonies © John Innes Centre 3: Blue haloes surrounding Streptomyces coelicolor colonies are secreted 3 4 actinorhodin (an antibiotic) © John Innes Centre 4: Antibiotic droplet secreted by Streptomyces coelicolor © John Innes Centre PhD thesis, Faculty of Sciences, Ghent University, Ghent, Belgium. Publicly defended in Ghent, December 9th, 2004. Examination Commission PROF. DR. J. VAN BEEUMEN (ACTING CHAIRMAN) Faculty of Sciences, University of Ghent PROF. DR. IR. J. SWINGS (PROMOTOR) Faculty of Sciences, University of Ghent DR. M. VANCANNEYT (CO-PROMOTOR) Faculty of Sciences, University of Ghent PROF. DR. M. GOODFELLOW Department of Agricultural & Environmental Science University of Newcastle, UK PROF. Z. LIU Institute of Microbiology Chinese Academy of Sciences, Beijing, P.R. China DR. D. LABEDA United States Department of Agriculture National Center for Agricultural Utilization Research Peoria, IL, USA PROF. DR. R.M. KROPPENSTEDT Deutsche Sammlung von Mikroorganismen & Zellkulturen (DSMZ) Braunschweig, Germany DR.
    [Show full text]
  • Evolution of the Streptomycin and Viomycin Biosynthetic Clusters and Resistance Genes
    University of Warwick institutional repository: http://go.warwick.ac.uk/wrap A Thesis Submitted for the Degree of PhD at the University of Warwick http://go.warwick.ac.uk/wrap/2773 This thesis is made available online and is protected by original copyright. Please scroll down to view the document itself. Please refer to the repository record for this item for information to help you to cite it. Our policy information is available from the repository home page. Evolution of the streptomycin and viomycin biosynthetic clusters and resistance genes Paris Laskaris, B.Sc. (Hons.) A thesis submitted to the University of Warwick for the degree of Doctor of Philosophy. Department of Biological Sciences, University of Warwick, Coventry, CV4 7AL September 2009 Contents List of Figures ........................................................................................................................ vi List of Tables ....................................................................................................................... xvi Abbreviations ........................................................................................................................ xx Acknowledgements .............................................................................................................. xxi Declaration .......................................................................................................................... xxii Abstract .............................................................................................................................
    [Show full text]
  • Identification of the Thiazolyl Peptide GE37468 Gene Cluster from Streptomyces ATCC 55365 and Heterologous Expression in Streptomyces Lividans
    Identification of the thiazolyl peptide GE37468 gene cluster from Streptomyces ATCC 55365 and heterologous expression in Streptomyces lividans Travis S. Young and Christopher T. Walsh1 Harvard Medical School, Armenise D1, Room 608, 240 Longwood Avenue, Boston, MA 02115 Contributed by Christopher T. Walsh, June 29, 2011 (sent for review June 6, 2011) Thiazolyl peptides are bacterial secondary metabolites that teins (10–13). The mature antibiotic arises from a structural gene potently inhibit protein synthesis in Gram-positive bacteria and encoding a 50–60 amino acid preprotein consisting of a 40–50 malarial parasites. Recently, our laboratory and others reported amino acid N-terminal leader peptide (residues −50 to −1) and that this class of trithiazolyl pyridine-containing natural products a14–18 amino acid C-terminal region (residues +1 to +18), is derived from ribosomally synthesized preproteins that undergo which becomes the final product scaffold (3). Flanking the struc- a cascade of posttranslational modifications to produce architectu- tural gene are encoded enzymes involved in peptide maturation, rally complex macrocyclic scaffolds. Here, we report the gene which appear to mimic the biosynthetic logic for microcin B17, cluster responsible for production of the elongation factor Tu lantibiotic, and cyanobactin antibiotic peptides (14). These (EF-Tu)-targeting 29-member thiazolyl peptide GE37468 from enzymes include lantibiotic-type dehydratases that form dehydro Streptomyces ATCC 55365 and its heterologous expression in the amino acids, cyclodehydratase and dehydrogenase enzymes model host Streptomyces lividans. GE37468 harbors an unusual involved in the formation of thiazoles/oxazoles, and a novel β-methyl-δ-hydroxy-proline residue that may increase conforma- enzyme(s) involved in the formation of the central pyridine/ tional rigidity of the macrocycle and impart reduced entropic costs piperidine ring.
    [Show full text]
  • Thiocillin and Micrococcin Exploit the Ferrioxamine Receptor of Pseudomonas Aeruginosa for Uptake
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.23.057471; this version posted April 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Thiocillin and Micrococcin Exploit the Ferrioxamine Receptor of Pseudomonas aeruginosa for Uptake 2 Derek C. K. Chan and Lori L. Burrows* 3 Michael G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and 4 Biomedical Sciences, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada 5 KEYWORDS: drug discovery, mechanism of uptake, thiopeptide, antimicrobial activity, siderophore, trojan 6 horse, 7 ABSTRACT 8 Thiopeptides are a class of Gram-positive antibiotics that inhibit protein synthesis. They have been 9 underutilized as therapeutics due to solubility issues, poor bioavailability, and lack of activity against 10 Gram-negative pathogens. We discovered recently that a member of this family, thiostrepton, has activity 11 against Pseudomonas aeruginosa and Acinetobacter baumannii under iron-limiting conditions. 12 Thiostrepton uses pyoverdine siderophore receptors to cross the outer membrane, and combining 13 thiostrepton with an iron chelator yielded remarkable synergy, significantly reducing the minimal 14 inhibitory concentration. These results led to the hypothesis that other thiopeptides could also inhibit 15 growth by using siderophore receptors to gain access to the cell. Here, we screened six thiopeptides for 16 synergy with the iron chelator deferasirox against P. aeruginosa and a mutant lacking the pyoverdine 17 receptors FpvA and FpvB.
    [Show full text]
  • Supporting Information Appendix: Media Compositions
    Supporting Information Appendix: Media compositions Seed media (2% glucose, 0.5% yeast extract, 0.5% meat extract, 0.5% peptone, 0.3% hydrolyzed casein, 0.15% NaCl). AF/MS media (2% glucose or 3% dextrin, 0.2% yeast extract, 0.8% organic soybean flour, 0.1% NaCL, 0.4% CaCO3) (1). Minimal MG Base (for 1L: 50 g maltose monohydrate, 0.2 g MgSO4 heptahydrate, 9 mg FeSO4 heptahydrate, 1 g CaCl2 monohydrate, 1 g NaCL, 21 g 3(N-morphilino)propanesulphonic acid, 11.23 g monosodium glutamate monohydrate, 15 mL 1M potassium phosphate buffer pH = 6.5, 4.5 mL of trace mineral solution consisting of 39 mg CuSO4, 5.7 mg H3BO3, 3.7 mg (NH4)6Mo7O24 tetrahydrate, 6.1 mg MnSO4 monohydrate, 880 mg ZnSO4 heptahydrate in 1 L water) (2). Minimal Media C (for 1L: 5 g L-glutamate, 1 g arginine, 1 g aspartate, 0.5 g K2HPO4 heptahydrate, 1 g MgSO4 heptahydrate, 2 g Na2SO4, 0.01 g ZnSO4 heptahydrate, 0.02 g FeSO4 heptahydrate, 3 g CaCO3, 40 g glucose) (3). J Media (10% sucrose, 3% tryptone soya, 1% yeast extract, 1% MgCl2 hexahydrate) (2). SFM (soya flour mannitol) agar plates (2 % organic soya flour, 2 % mannitol, 2% agar, tap water) (2). General Methods, Materials, and Instrumentation: All DNA manipulations (sub-cloning) were carried out in DH5α E. coli (Zymo Research). Streptomyces ATCC 55365 was obtained from American Type Culture Collection (Manassas, VA) and E. coli BW25113, E. coli BT340, plasmid pKD46, and plasmid pKD3 were obtained from the E. coli Genetic Stock Center (CGCS, Yale University).
    [Show full text]
  • Production of an Antibiotic-Like Activity by Streptomyces Sp. COUK1 Under Different Growth Conditions Olaitan G
    East Tennessee State University Digital Commons @ East Tennessee State University Electronic Theses and Dissertations Student Works 8-2014 Production of an Antibiotic-like Activity by Streptomyces sp. COUK1 under Different Growth Conditions Olaitan G. Akintunde East Tennessee State University Follow this and additional works at: https://dc.etsu.edu/etd Part of the Biology Commons Recommended Citation Akintunde, Olaitan G., "Production of an Antibiotic-like Activity by Streptomyces sp. COUK1 under Different Growth Conditions" (2014). Electronic Theses and Dissertations. Paper 2412. https://dc.etsu.edu/etd/2412 This Thesis - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact [email protected]. Production of an Antibiotic-like Activity by Streptomyces sp. COUK1 under Different Growth Conditions A thesis presented to the faculty of the Department of Health Sciences East Tennessee State University In partial fulfillment of the requirements for the degree Master of Science in Biology by Olaitan G. Akintunde August 2014 Dr. Bert Lampson Dr. Eric Mustain Dr. Foster Levy Keywords: Streptomyces, antibiotics, natural products, bioactive compounds ABSTRACT Production of an Antibiotic-like Activity by Streptomyces sp. COUK1 under Different Growth Conditions by Olaitan Akintunde Streptomyces are known to produce a large variety of antibiotics and other bioactive compounds with remarkable industrial importance. Streptomyces sp. COUK1 was found as a contaminant on a plate in which Rhodococcus erythropolis was used as a test strain in a disk diffusion assay and produced a zone of inhibition against the cultured R.
    [Show full text]
  • Genomic and Phylogenomic Insights Into the Family Streptomycetaceae Lead to Proposal of Charcoactinosporaceae Fam. Nov. and 8 No
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.08.193797; this version posted July 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Genomic and phylogenomic insights into the family Streptomycetaceae 2 lead to proposal of Charcoactinosporaceae fam. nov. and 8 novel genera 3 with emended descriptions of Streptomyces calvus 4 Munusamy Madhaiyan1, †, * Venkatakrishnan Sivaraj Saravanan2, † Wah-Seng See-Too3, † 5 1Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, 6 Singapore 117604; 2Department of Microbiology, Indira Gandhi College of Arts and Science, 7 Kathirkamam 605009, Pondicherry, India; 3Division of Genetics and Molecular Biology, 8 Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, 9 Malaysia 10 *Corresponding author: Temasek Life Sciences Laboratory, 1 Research Link, National 11 University of Singapore, Singapore 117604; E-mail: [email protected] 12 †All these authors have contributed equally to this work 13 Abstract 14 Streptomycetaceae is one of the oldest families within phylum Actinobacteria and it is large and 15 diverse in terms of number of described taxa. The members of the family are known for their 16 ability to produce medically important secondary metabolites and antibiotics. In this study, 17 strains showing low 16S rRNA gene similarity (<97.3 %) with other members of 18 Streptomycetaceae were identified and subjected to phylogenomic analysis using 33 orthologous 19 gene clusters (OGC) for accurate taxonomic reassignment resulted in identification of eight 20 distinct and deeply branching clades, further average amino acid identity (AAI) analysis showed 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.08.193797; this version posted July 8, 2020.
    [Show full text]
  • During the Course of Screening for Streptothricin Antibiotics, a Variant Of
    VOL. XXVII NO. 7 THE JOURNAL OF ANTIBIOTICS 535 A NEW STREPTOTHRICIN ANTIBIOTIC, R4H YOSUKE SAWADA and HYOZO TANIYAMA Faculty of Pharmaceutical Sciences, Nagasaki University, Nagasaki, Japan NOBUO HANYUDA, HISASHI HAYASHI and TADASHI ISHIDA Research Division, Toa Nutritional Chemical Ind. Co., Ltd., Fukushima, Japan (Received for publication January 21, 1974) An antibiotic R4H exhibiting no delayed toxicity was isolated from the fermenta- tion broth of Streptomyces lavendulae strain R4. It was active against Gram-positive and -negative bacteria and Mycobacterium. R4H was converted to racemomycin-A and racemomycinic-A acid by mild hydrolysis. During the course of screening for streptothricin antibiotics, a variant of Streptomyces lavendulae was found to produce new antibiotics along with the known streptothricins. The taxonomic and fermentation characteristics of the tentatively named strain R4, its isolation procedures, and the physicochemical and biological properties of the antibiotic R4H are described in this communication. Characteristics of Strain R4 The strain is of a Streptomyces isolated from a soil sample obtained in Fukushima city, in northeastern part of Japan. Most of the general procedures reported by SHIRLING et a1.1) and WAKSMAN2,3)were used in determination of morphological and physiological properties. PRIDHAM-GOTTLIEBbasal medium was used for the carbon utilization test. Culture was grown at 28°C for 14 days unless other- wise mentioned. Color comparisons were made using the standard color table (JIS Z-8721), and the results are given as color name, number of hue, luminosity, and saturation, in that order. 1. Morphological Characteristics The vegetative mycelium of the strain R4 is well-branched but does not fragment into cocoid or bacillary forms in liquid media.
    [Show full text]